A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses)

  • days left to enroll
  • participants needed
  • sponsor
    Taisho Pharmaceutical Co., Ltd.
Updated on 1 September 2021


A Phase 1, Single-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending and Multiple Dose of TS-172 in Healthy Adult Subjects

Condition Healthy Adult Subjects
Treatment Placebo, TS-172
Clinical Study IdentifierNCT04979572
SponsorTaisho Pharmaceutical Co., Ltd.
Last Modified on1 September 2021


Yes No Not Sure

Inclusion Criteria

Japanese healthy males aged 20 years or older but less than 40 years at the time of informed consent
Those with a BMI of 18.5 or more and less than 25.0 at screening test
Those who are able to receive the explanation before participating in the study, understand the content of the study, and provide written informed consent by the subjects themselves

Exclusion Criteria

Subjects who have any disease and are not considered healthy subjects based on the medical judgment of the principal investigator or sub-investigator
Those who correspond to any of the following about bowel movements
Repeated diarrhea (Bristol Stool Form Score [BSFS] score of 6 or higher) on a daily basis
Repeated constipation (no defecation for 2 days or more in a week) on a daily basis
Those who correspond to any of the following about bowel movements in the 7 days before administration
Diarrhea on 2 or more days in 7 days
or more days without a bowel movement in 7 days
Those who have a history of gastrointestinal ulceration
Those who correspond to any of the following about infection
Positive for SARS-CoV-2 in the nucleic acid amplification test performed at the time of admission
Suspected of having COVID-19
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note